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Background: There are safety concerns with using unlicensed medicines across 
countries including Brazil. Consequently, this needs to be evaluated and concerns 
address if pertinent. Aim: Investigate such purchases by the Brazilian Federal 
Government from 2004 to 2013. Methods: Procurement data from a public-access 
databank that contains procurement information of the Brazilian Federal Government. 
Each procured item was cross-referenced to its active drug approval status in the 
Brazilian National Register (DOU). Exploratory analysis and trend measures were 
performed for the variables for mapping and characterizing the purchases of non-market 
approved drugs. Results: 614 (0.14%) purchases in ten years corresponding to 65 
unlicensed medicines ± some of which had orphan drug status ±  and 48 different active 
substances; with a growing trend in recent years. Medicines in 51% of purchases were 
procured before obtaining marketing approval ± with eventual refusals occurring in 
17.8% and cancellation due to lack of efficacy and/or safety concerns in 1.1%. Health 
litigation accounted for 81.9% of purchases and growing in recent years. Conclusions: 
Overall a low rate of unlicensed medicine use. However, there are concerns given the 
current regulations in Brazil and the recent increase in the use of unlicensed medicines 









Risks associated with medicines devoid of robust evidence of safety and efficacy are not 
uncommon. Withdrawals of medicines are much more frequent for problems regarding 
safety than for a lack of efficacy [1]. Several years may go by with hazardous exposure 
before a licensed medicine ± approved by a regulatory body ± may be removed from the 
market [1-4]. Careful assessment of new medicines for first-time approval, or 
subsequent re-approval or withdrawal, aims to protect patients and save important 
resources. This is especially important if the new medicine is to be used in a patient 
population with greater numbers of elderly, and a broader range of co-morbidities, than 
seen in the clinical trials [1-3]. 
 
In Brazil, licensing is mandatory for all marketed medicines (imported or locally 
produced). Drug approval is the responsibility of the Ministry of Health (MoH) through 
the Brazilian Health Surveillance Agency (ANVISA). Medicines were originally 
licensed for a five-year period [5], after which a new assessment for renewal had to be 
made. Recent legislation has expanded this period to ten years, depending on the type of 
medicine and the health risk involved [6]. Drugs for rare diseases, defined in Brazil as 
those affecting 65 in 100.000 individuals, receive orphan drug status [7,8], but are also 
subject to the same regulation. Experimental medicines under clinical control are 
exempt for licensing requirements for a three-year period. After this period, the 
medicine must undergo assessment for market approval [5]. In 2013 and 2014, Brazilian 
regulatory authorities published measures to speed up the drug approval process 
introducing multiple flexibilities for concession of licenses or for the waiver of 
licensing requirements [9,10].  
 
Brazilian legislation also impedes dispensing and financing of unlicensed medicines in 
all levels of the public health system [11]. A fundamental requirement for the public 
procurement of medicines is a valid license. Specific legislation also stipulates that the 
government may only supply licensed medicines in evidence-based indications [5]. 
 
Health management in Brazil has been plagued by litigation since the late 1980s. 
Jurisprudence in Brazil understands health as a fundamental right and access to 
medicines as a means to attain health. Litigation for access to pharmaceuticals and 
health products warrants total access to plaintiffs´ demands. Objects of litigation 
sometimes include medicines and procedures without marketing authorization or 
unavailability in the Brazilian Health System (SUS). Paradoxically, arbitrary 
interpretation of this rule may lead to the supply of medicines which have not 
undergone adequate efficacy and safety assessments [12-14], and may not provide value 
for money. This has proven to be an opportunity for pharmaceutical companies to 
further exert a strong influence on prescribers and patient organizations, enlarging 
markets for costly medicines, including new formulations [14]. There is now evidence 
that lawsuits have prompted the incorporation of some new medicines into Brazilian 
government funding lists, even without clear superiority of efficacy, safety, quality or 
cost-effectiveness, compared to already available therapies [15]. Health litigation for 
access to medicines may also lead to judicial enforcement of purchases of medicines 




To our knowledge, no information on procurement of unlicensed medicines in Brazil 
has yet been published. Consequently, there is a need to monitor government purchases, 
and possibly disclose important trends on medicine adoption and procurement, that may 
circumvent licensing. This study aims to investigate purchases of unlicensed medicines 
by the Brazilian Federal Government, from 2004 to 2013 as a basis for recommending 
future initiatives if pertinent. 
 
Methods 
We used the General Services Administration Database (Sistema Integrado de 
Administração de Serviços Gerais - SIASG), a public±access data bank that contains 
tendering information of the Brazilian Federal Government, for our longitudinal study.  
 
Purchases with incomplete identification of medicines, according to the Brazilian 
Nonproprietary Name (INN), dosage form and concentration, were excluded. 
Subsequent exclusions were purchases of (i) compounded medicines, (ii) medicines that 
had a license waiver according to ANVISA regulations [17] and (iii) 
radiopharmaceuticals (for which licensing regulations only began in 2009). 
 
In order to cross-check licensing information of medicines in individual purchases 
obtained in SIASG, we consulted the Brazilian National Register, the daily posting of 
the Brazilian Federal Government (Diário Oficial da União ± DOU) and documents 
from ANVISA for active licensing status.  
 
Expenditure of unlicensed medicines were obtained through total volume and price of 
each item, and adjusted to December 2013, by means of a widely used pricing deflator, 
the IPCA (Índice de Preços ao Consumidor Amplo ± IPCA) obtained from the Institute 
of Applied Economic Research (Instituto de Pesquisa Econômica Aplicada ± IPEA ± 
http://www.ipeadata.gov.br/IBGE). Expenditures were expressed in US$ using the 2013 
mean annual exchange rate (1US$ = R$ 2.157) according to the U.S. Federal Reserve 
Bank (https://www.federalreserve.gov/releases/g5a/current/). Medicines responsible for 
major expenditures in the period were identified and their costs per monthly treatment 
of a 70kg adult calculated and inserted. 
 
Six categories of unlicensed medicines were identified: (a) license obtained after 
purchase; (b) license cancelled by ANVISA for lack of efficacy and/or safety reasons; (c) 
license expired; (d) first license or renewal refused by ANVISA; (e) unlicensed 
concentration and/or dosage form; (f) license cancellation claimed by the manufacturer, 
and (g) license not found. Medicines were cross-FKHFNHGIRUWKHLUµRUSKDQGUXJVWDWXV¶
according to FDA regulations [18]. This is because in Brazil there is no drafted list of 
orphan drugs; consequently, the FDA list was used. Drugs for rare diseases are referred 
to as orphan drugs in the US. The FDA defines rare disease as (a) those affecting less than 
200,000 people and (b) as those affecting more than 200,000 people but for which there 
LVQRµUHDVRQDEOHH[SHFWDWLRQ¶RIGHYHORSPHQWRIDGUXJWKDWZLOOKDYHLWVGHYHORSPent 
costs recovered from sales within the country [18].  
 
Information was obtained for the following variables: date of purchase, name of drug, 
dosage form and concentration, purchase strategy (tender, auction, tender waiver due to 
a variety of situations, including sole source), purchasing justification 
(regular/emergency procurement, litigation-related procurement, no information) and 
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name of purchasing institution (Ministry of Health, Ministry of Education, Ministry of 
Defense and others). Unlicensed medicines were classified by the Anatomical 
Therapeutic Chemical Classification (ATC) System, to the fourth or fifth level when 
this existed (http://www.whocc.no/atc_ddd_index/). 
 
Exploratory analysis was performed for all variables, using the Excel software 
(Microsoft Corp. United States). Linear tendencies were plotted for the following 
variables: number of purchases, number of unlicensed medicines and number of active 
substances purchased along the period. Expenditure trends were plotted using moving 
averages method, because of intense variation and small magnitude. This method is a 
statistical indicator that helps to minimize acute fluctuations and show longer-term 
trends [19]. There were no ethical constraints to data access or analysis, since the entire 
study was based on public±access data. Ethical legislation exempted the study from 




From 2004 to 2013, 465,203 purchases of medicines with complete information were 
registered in SIASG. Of these, 18,083 were excluded, resulting in 447,120 purchases 
examined as to licensing status. There were 614 (0.14%) purchases of unlicensed 
medicines in the ten±year period, with a total expenditure of approximately US$169 
million. Figure 1 shows the trends for the number of purchases, unlicensed medicines, 





Figure 1. Federal Government Purchases: number and trend of purchases of unlicensed 
medicines (A), unlicensed medicines (B), active substances (C) and expenditures in USD 





These 614 purchases correspond to 65 unlicensed medicines (active substance, strength 
and dosage form), comprising 48 different active substances. From 2004, the number of 
unlicensed medicines showed a slight increase over time. The number of purchases 
peaked in 2008 (147 purchases, 15 different medicines and 14 distinct active 
substances) and in 2013 (174 purchases, 38 medicines and 29 active substances) (Figure 
1). Expenditures for 2008 and 2013 were USD 24 and USD 68 million, respectively. In 
2008, galsulfase 1 mg/mL accounted for 59.9% (88/147) of purchases, while in 2013 
39.7% (69/174) of purchases were for eculizumab 10 mg/mL.  
 
Among the 48 different active substances present in medicines with an unlicensed 
status, 20 (corresponding to 30 different medicines) were medicines that were used for 
the treatment of rare diseases. In the ten-year period, three medicines had considerable 
expenditure: eculizumab (USD 370,654,400.79), taliglucerase alfa (USD 
128,066,691.25) and galsulfase (USD 86,059,574.27). All three are considered orphan 
drugs, employed for rare diseases: eculizumab for paroxysmal nocturnal 
haemoglobinuria (PNH), taliglucerase alfa for Gaucher´s disease and galsulfase for 
treatment of Mucopolyssacharidosis Type VI (Maroteaux-Lamy disease). For a 70kg 
adult, a one-month treatment with eculizumab cost approximately USD 2.25 million, 
while for taliglucerase alfa the cost per patient per month is USD3660. A one-month 




Box 1 presents active substances according to unlicensed medicine categories. 
Medicines in more than half of total purchases were procured before obtaining 
marketing authorization (51%). Licensing refusal occurred in 17.8% of purchases and 
cancellation due to safety concerns and/or lack of efficacy in 1.1%.  
 
Box 1. Purchases of unlicensed medicines, according to category. Brazil, 2004-2013 
 
Category Number of 
purchases (%) 
Medicine 
license obtained after 
purchase 
313 (51.0) agalsidase alfa 1mg/mL injectable*, taliglucerase alfa 200 
UI injectable*, brentuximab vedotine 50 mg injectable*, 
cinacalcet 30 mg capsule*, C1 esterase inhibitor 500 UI 
injectable, darunavir 300 mg tablet , dasatinib 100 mg 
tablet*, erlotinib 100 mg tablet, erlotinib 150 mg tablet, 
etravirine 100 mg tablet, fidaxomicin 200 mg tablet, 
galsulfase 1 mg/mL injectable*, gefitinib 250 mg tablet*, 
idursulfase 2 mg/mL injectable*, lacosamide 50 mg tablet, 
tipranavir 250 mg capsule, tirofiban 0.25 mg/mL injectable 
license not found 131 (21.3) eculizumab 10 mg/mL injectable*, stiripentol 500 mg 
capsule, nitisinone 5 mg capsule*, nitisinone 10 mg 
capsule*, pegaspargase 750 UI/mL injectable*, ponatinib 
45 mg tablet*, rufinamide 200 mg tablet, tafamidis 20 mg 
capsule, tetracosactide 0.25 mg injectable, tetracosactide 1 
mg/mL injectable, trientine 250 mg tablet* 
first license or renewal 
refused 
109 (17.8) clofarabine 1 mg/mL injectable, foscarnet 24 mg/mL 
injectable, hematin 25 mg/mL, lenalidomide 5 mg capsule*, 
lenalidomide 10 mg capsule*, lenalidomide 25 mg 
capsule*, levetiracetam 250 mg tablet, levetiracetam 500 
mg tablet, lomitapide 5 mg capsule*, lomitapide 10 mg 
capsule*, lomitapide 20 mg capsule*, mercaptamine 50 mg 
capsule*, mercaptamine 150 mg capsule*, mercaptamine 
6,5 mg/mL ophthalmic solution*, regorafenib 40 mg 
tablet*, ruxolitinib 5 mg tablet* 
license expired 36 (5.9) artesunate 50 mg tablet , cidofovir 75 mg/mL injectable, 
disopyramide 250 mg dragee, miltefosine 5 mg capsule*, 
miltefosine 10 mg capsule*, pentamidine 300 mg 
injectable, pentosan 100 mg capsule, procarbazine 50 mg 




17 (2.8) denosumab 70 mg/mL injectable*, diazoxide 25 mg 
capsule, diazoxide 50 mg/mL oral suspension, hematin 313 
mg injectable, sultiame 50 mg tablet 
license canceled for 
safety reasons and/or 
lack of efficacy  
7 (1.1) drotrecogin alfa 5 mg injectable, drotrecogin alfa 20 mg 
injectable, rosiglitazone 4 mg tablet, rosiglitazone 8 mg 
tablet 
license cancelation 
claimed by the 
manufacturer 
1 (0,2) barbexaclone 100 mg tablet 
*Orphan drug status (FDA, 2017) 
  
Table 1 shows purchases according to ATC classification (therapeutic subgroup). 
Purchases of medicines acting in the alimentary tract and metabolism (29.0%) and 




Table 1. Purchases of unlicensed medicines, according to ATC classification. Brazil, 
2004-2013 
Therapeutic Subgroup Number of purchases (%) 
A16 - Alimentary tract and 
metabolism  178 (29.0) 
L04 - Immunosuppressants  114 (18.6) 
B01 - Antithrombotic agents  83 (14.4) 
J05 - Antivirals for systemic use  42 (6.8) 
N03 - Antiepileptics  41 (6.7) 
C10 - Lipid modifying agents  34 (5.5) 
L01 - Antineoplastic agents  33 (5.4) 
Others 89 (14.5) 
 
 The Ministry of Health (MoH) was responsible for the majority (86.0%) of unlicensed 
medicines purchases.  
 
The predominant purchase strategy was unspecified tender waiver carried out for 511 
(83.2%) purchases, the majority of which (96.9%) were implemented by the Ministry of 
Health. Auctions accounted for 80 purchases of which 51.3% were performed by the 
Ministry of Education.  
 
Purchasing justification was not informed in 13.8% of purchase entries, with a marked 
decrease in the last three years of the study period (0.49% in 2013). Health litigation 
accounted for 81.9% of total purchases of unlicensed medicines in Brazil between 2004 
to 2013. In 2013, however, health litigation alone was responsible for 96.6% of 










During the ten±year period, the Brazilian Government procured a variety of unlicensed 
medicines, some of which were bought repeatedly, contrary to federal law, with all 
variables showed a rising trend over the ten-year period (Figure 1). This observation 
may indicate several factors are involved including prescriptions outside of official 
treatment protocols, pressures exerted by litigation for unlicensed medicines [13], or the 
flexibility of import regulations, facilitating the purchase of unlicensed medicines [9]. 
 
Whilst the overall number of purchases of unlicensed medicines is small (0.14%), the 
rise in unlicensed medicines purchases in 2013 is worrying and may be associated with 
new legislation. Decree n° 8,077/2013 exempts from market approval strategic 
pharmaceuticals and health products supplied by international organizations for use in 
government programs. Moreover, the new legislation eases government medicines 
purchases through simplified licensing procedures in the case of severe health risks or 
absence of licensed therapeutic alternatives [9].  
 
In addition, although the number of federal purchases of unlicensed medicines has 
overall been small, the event itself should have been exceptionally rare. Purchases of 
unlicensed medicines violate article 19-T of Law 12.401/2011, which explicitly states 
that the government may not pay for or reimburse locally produced or imported 
unlicensed medicines or products; or experimental clinical or surgical procedures or 




Several of the medicines had orphan status. Seventeen medicines involved in large 
numbers of purchases (313) obtained licenses after their purchase. Agalsidase alfa 1 
mg/mL (injectable), cinacalcet 30 mg (capsule), galsulfase 1 mg/mL (injectable), 
gefitinib 250 mg (tablet), idursulfase 2 mg/mL (injectable), lacosamide 50 mg (tablet), 
tipranavir 250 mg (capsule) and tirofiban 0.25 mg/mL (injectable) were purchased 
continuously for three years or more, before obtaining marketing authorization. 
Increases in unlicensed purchases in light of new flexibilities, might actually result in 
more rapid licensing and adoption by the health system, perpetuating this cycle [21]. 
Recurrent purchases of several unlicensed medicines over time may represent one of 
two situations: either a pressure mechanism for obtaining marketing approval or as 
purposeful neglect of medicine regulation in the country. 
 
Other significant purchases were related to the refusal of the first license or of renewal 
(109), which is a noteworthy finding, considering ANVISA´s role as a regulatory 
agency. In ANVISA´s website, information on this issue is not forthcoming and a 
JHQHULFODEHOµQRQ-FRQIRUPLW\WROHJLVODWLRQ¶LVJLYHQDVDUHDVRQIRUUHIXVDO [22]. A 
relevant point must be made regarding the availability and transparency of information 
in ANVISA´s website, which may have an important bearing upon our results. Lack of 
information, unavailability of market approval histories, and overall delay in 
information updates were difficulties encountered during data collection and analysis.  
 
The time span for market approval procedures in Brazil has been variable [23] in spite 
of 90±day threshold established by current legislation. No licensing information was 
found for 131 purchases, which may be explained by perceived length of market 
approval time, leading to disinterest in licensing submission. Moreover, manufacturers 
may not be interested in licensing their new medicine in each country. Greater profits 
may result from health litigation, since it obliges the government to buy medicines, 
licensed or not, commanding higher prices and less competition because of emergency 
procurement procedures [14,16].   
 
Four medicines had licenses cancelled due to safety reasons and/or lack of efficacy. 
Drotrecogin alfa was voluntarily removed from the international market by Eli Lilly due 
to failure to show a survival benefit and excessive bleeding. Rosiglitazone had its 
approval cancelled by ANVISA and by the European Medicines Agency (EMA) due to 
severe cardiovascular effects. 
 
The recent Brazilian legislation [10] considers authorized importation of unlicensed 
medicines for individual use in exceptional circumstances. Various unlicensed 
medicines, including products with an expired license or with a license refusal that were 
identified by this study, are present in the list of medicines issued by ANVISA for this 
purpose [24]. These cases highlight the importance of a regulatory agency´s role. 
Efficacy and safety are central to pharmaceutical regulation, which in the present 
situation appears second in line to demands and pressures resulting from litigation. 
In our study, health litigation was an overwhelming factor for purchases of unlicensed 
medicines. In the last year of the study period, the proportion of purchases resulting from 
litigation rose to 96.6% of total purchases. This result is corroborated by several studies 
that show the use of judicial demands as a strategy for obtaining access to marketing 
approval or unlicensed medicines in Brazil [13,14], while ignoring health regulations and 
exposing users to unnecessary health hazards. Since the early 1990s, litigation has 
involved not only high-cost medicines and those for overall high-cost treatments, but also 
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Primary Health Care (PHC) medicines that may not be delivered in a timely fashion by 
municipal governments. According to the law, responsibilities for delivery are very 
specific ± municipal governments should dispense PHC medicines, States some high-cost 
drugs and the federal level must deliver medicines for neglected diseases and most of the 
very costly newer medicines.  
 
Not surprisingly, the Ministry of Health is the main federal purchasing agent of 
unlicensed medicines. In Brazil, litigation against the public health system has been 
rising steeply in the last few years and, in spite of state and municipal roles as 
defendants, very high-cost medicines demands usually bring the Ministry to court, 
because highly-complex care is concentrated in federal and university hospitals 
[13,25,26].  
 
Alimentary Tract and Metabolism Agents, Immunosuppressants, and Antithrombotic 
Agents formed the majority of unlicensed medicines, due to great number of purchases 
related to galsulfase (A16AB08), lenalidomide (L04AX04) and tirofiban (B01AC17), 
respectively. For the A16 subgroup, especially, 98.9% of purchases during the 10-year 
period were consequences of litigation. However, not all unregistered medicines were 
expensive (exceptions, for instance, include miltefosine, barbexaclone, and lacosamide). 
But most of the A16 medicines are very high-cost enzymes for rare diseases, such as 
Gaucher´s disease and for PNH. The extreme costs calculated for monthly treatments 
may be result of litigation but may alternatively be due to lack of negotiations to lower 
prices. The median prices we obtained coincide with those from 2014 [27]. Sartori and 
co-workers (2012) examined litigation for agalsidase alfa in the state of Rio Grande do 
Sul until 2007, and found that most prescriptions originated in university hospitals. At 
this time, agalsidase alfa had been approved by the EMA, but licensing in Brazil only 
happened in 2009 [28].   
Litigation has spread in Brazil, appreciably increasing medicine expenditure in the 
states, municipalities and Federal Government. Ministry of Health (MoH) expenditures 
with health litigation have been estimated at US$750 million from 2012 to 2014, with 
expenditure rising from US$188.32 million in 2012 to US$359.05 million in 2014 [29]. 
This is a growing concern especially regarding the particular characteristics of 
purchases resulting from litigation. Decisions are usually made in haste and medicines 
are not included in forecasting. Because purchases usually forgo regular tendering 
procedures, different waivers are applied, and the government is apt to relinquish 
bargaining power, resulting in higher costs for the system [14,16].  
 
As a result, health litigation frequently causes negative social consequences and 
produces detrimental resource allocation, causing strain on existing health services and 
particularly pharmaceutical services [30]. As a result, the goals of universal access to 
healthcare in Brazil may be difficult to sustain. 
 
We accept that one of the limitations of this study on purchases of unlicensed medicines 
in Brazil is that it is based on secondary data. Although an original effort to approach 
the issue has been made, some limitations should additionally be mentioned. The 
SIASG database, although comprehensive in listing federal purchases, also presented 
inconsistencies regarding certain variables, such as the purchase strategy, purchasing 
justification and prices. In addition, existing information in the database is not always 
complete or self-explanatory. Nevertheless, the data bank has improved over the years, 
permitting a series of studies on federal procurement in Brazil [31,32]. It must be 
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emphasized that SIASG procurement data offer a proxi for consumption and, as such, 




Our study presents the scenario of federal purchases of unlicensed medicines in Brazil 
from 2004 to 2013, as well as possible determinants and consequences.  
 
Total volume of purchases of unlicensed medicines was very small, but the number of 
events, which should have been very rare, was observed to increase during the study 
period. Health litigation is an important determinant for this rise and may result in 
premature licensing and untoward adoption by the health system.  
 
For these reasons, we recommend a careful review of purchase demands of unlicensed 
medicines and their submission to health assessment procedures before purchase. 
Although these purchases might be authorized in very exceptional circumstances, 
efficacy, safety, quality and effectiveness of medicines must be acknowledged. Given 
the current regulations and the context of health litigation in Brazil, the recent surge of 
unlicensed medicines procurement is likely to increase, which is a concern. Trends in 
purchases of unlicensed medicines should be looked into, especially determining the 
role of litigation. This is also important as Brazil´s regulatory agency, ANVISA, is a 
reference for the Latin American region and several other Latin American countries are 
undergoing the same health litigation phenomenon, which is an increasing concern. 
 
Key messages 
x A valid license is a fundamental requirement for the public procurement of medicines 
in Brazil, and legislation binds the government to supply licensed medicines in 
evidence-based indications. 
x Health litigation for access to medicines, however, has led to judicial enforcement of 
medicines purchases, disrupting normal pathways  
x As a result, paradoxically, at times making drug approval regulations secondary to 
judicial decisions. 
x An investigation from 2004 to 2013 showed that 65 unlicensed medicines were linked 
to 614 purchases over this ten-year span, with numbers rising in 2013 
x Health litigation accounted for 81.9% of purchases during the ten-year period. 
x Efficacy and safety are central to pharmaceutical regulation where patients are 
concerned, which at times appear secondary to demands and pressures resulting from 
litigation. 
x Unlicensed medicines procurement in Brazil indicates the need for further strategies 
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